Vasculopathy in scleroderma

[1]  Y. Tada,et al.  A possible contribution of lipocalin‐2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis , 2015, The British journal of dermatology.

[2]  Shinichi Sato,et al.  Endothelin Receptor Blockade Ameliorates Vascular Fragility in Endothelial Cell–Specific Fli‐1–Knockout Mice by Increasing Fli‐1 DNA Binding Ability , 2015, Arthritis & rheumatology.

[3]  F. Lebrin,et al.  Pericytes as targets in hereditary hemorrhagic telangiectasia , 2015, Front. Genet..

[4]  Y. Tada,et al.  A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis , 2015, Experimental dermatology.

[5]  Y. Asano,et al.  Fibrosis, Vascular Activation, and Immune Abnormalities Resembling Systemic Sclerosis in Bleomycin‐Treated Fli‐1–Haploinsufficient Mice , 2015, Arthritis & rheumatology.

[6]  D. Huscher,et al.  Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group , 2014, Annals of the rheumatic diseases.

[7]  Maha M Coucha,et al.  Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control. , 2014, Life sciences.

[8]  K. Fujiu,et al.  Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis , 2014, Nature Communications.

[9]  Marzia Rossato,et al.  The role of genetics and epigenetics in the pathogenesis of systemic sclerosis , 2014, Nature Reviews Rheumatology.

[10]  K. Yanaba,et al.  Successful experience of rituximab therapy for systemic sclerosis‐associated interstitial lung disease with concomitant systemic lupus erythematosus , 2014, The Journal of dermatology.

[11]  S. Hsieh,et al.  Rituximab for refractory digital infarcts and ulcers in systemic sclerosis , 2014, Clinical Rheumatology.

[12]  A. Konradi,et al.  Effects of rituximab therapy on elastic properties of vascular wall in patients with progressive systemic sclerosis. , 2014, Clinical and experimental rheumatology.

[13]  Ming Li,et al.  Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction , 2014, Arthritis Research & Therapy.

[14]  Yoshiya Tanaka,et al.  Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis , 2013, Modern rheumatology.

[15]  S. Jimenez,et al.  Role of Endothelial to Mesenchymal Transition in the Pathogenesis of the Vascular Alterations in Systemic Sclerosis , 2013, ISRN rheumatology.

[16]  K. Chakravarty,et al.  Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. , 2013, QJM : monthly journal of the Association of Physicians.

[17]  A. Malik,et al.  Transcriptional regulation of endothelial cell and vascular development. , 2013, Circulation research.

[18]  Y. Tada,et al.  Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. , 2013, Rheumatology.

[19]  I. Komuro,et al.  Clinical correlation of brachial artery flow-mediated dilation in patients with systemic sclerosis , 2013, Modern rheumatology.

[20]  Y. Yamaguchi,et al.  Proangiogenic hematopoietic cells of monocytic origin: roles in vascular regeneration and pathogenic processes of systemic sclerosis. , 2013, Histology and histopathology.

[21]  M. Cutolo,et al.  Longterm Effects of Endothelin Receptor Antagonism on Microvascular Damage Evaluated by Nailfold Capillaroscopic Analysis in Systemic Sclerosis , 2013, The Journal of Rheumatology.

[22]  G. Mutlu,et al.  Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. , 2013, The American journal of pathology.

[23]  M. Matucci Cerinic,et al.  Bosentan fosters microvascular de-remodelling in systemic sclerosis , 2012, Clinical Rheumatology.

[24]  D. Daoussis,et al.  Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. , 2012, Seminars in arthritis and rheumatism.

[25]  M. Fujimoto,et al.  Impaired IL-17 Signaling Pathway Contributes to the Increased Collagen Expression in Scleroderma Fibroblasts , 2012, The Journal of Immunology.

[26]  D. Dragun,et al.  Ulnar artery occlusion is predictive of digital ulcers in SSc: a duplex sonography study. , 2012, Rheumatology.

[27]  Y. Tada,et al.  A Possible Contribution of Altered Cathepsin B Expression to the Development of Skin Sclerosis and Vasculopathy in Systemic Sclerosis , 2012, PloS one.

[28]  Daniel Dumitrescu,et al.  Imatinib mesylate for the treatment of pulmonary arterial hypertension , 2012, Expert opinion on investigational drugs.

[29]  A. Koch,et al.  Angiogenesis and Vasculopathy in Systemic Sclerosis: Evolving Concepts , 2012, Current Rheumatology Reports.

[30]  S. Jimenez,et al.  Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. , 2011, Arthritis & Rheumatism.

[31]  L. Lau.  CCN1/CYR61: the very model of a modern matricellular protein , 2011, Cellular and Molecular Life Sciences.

[32]  G. Chodorowska,et al.  Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. , 2011, Rheumatology.

[33]  K. Kinugawa,et al.  Significant attenuation of macrovascular involvement by bosentan in a patient with diffuse cutaneous systemic sclerosis with multiple digital ulcers and gangrene , 2011, Modern rheumatology.

[34]  M. Yoder,et al.  Endothelial progenitor cells: quo vadis? , 2011, Journal of molecular and cellular cardiology.

[35]  M. Mayes,et al.  Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial , 2010, Annals of the rheumatic diseases.

[36]  Shinichi Sato,et al.  Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis. , 2010, Rheumatology.

[37]  Y. Yamaguchi,et al.  Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis , 2010, Arthritis Research & Therapy.

[38]  Y. Francès,et al.  Endothelial function and hemodynamics in systemic sclerosis , 2010, Clinical physiology and functional imaging.

[39]  K. Phillips,et al.  Digital Ischemia in Scleroderma Spectrum of Diseases , 2010, International journal of rheumatology.

[40]  L. Chung,et al.  Digital Ischemic Loss in Systemic Sclerosis , 2010, International journal of rheumatology.

[41]  M. Fujimoto,et al.  Cell Adhesion Molecules Regulate Fibrotic Process via Th1/Th2/Th17 Cell Balance in a Bleomycin-Induced Scleroderma Model , 2010, The Journal of Immunology.

[42]  T. Kawabe,et al.  Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. , 2010, American journal of respiratory cell and molecular biology.

[43]  H. Mitsuya,et al.  Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis , 2010, Arthritis research & therapy.

[44]  L. Mouthon,et al.  Therapeutic options for systemic sclerosis related interstitial lung diseases. , 2010, Respiratory medicine.

[45]  M. Cutolo,et al.  Brachial Artery Endothelial-dependent Flow-mediated Dilation Identifies Early-stage Endothelial Dysfunction in Systemic Sclerosis and Correlates with Nailfold Microvascular Impairment , 2010, The Journal of Rheumatology.

[46]  D. Watson,et al.  Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. , 2010, The American journal of pathology.

[47]  D. Ingram,et al.  Identification of Endothelial Cells and Progenitor Cell Subsets in Human Peripheral Blood , 2010, Current protocols in cytometry.

[48]  J. Tervaert,et al.  Anti-endothelial cell antibodies in systemic sclerosis , 2010, Annals of the rheumatic diseases.

[49]  Y. Asano.  Future treatments in systemic sclerosis , 2010, The Journal of dermatology.

[50]  S. Hollenbeck,et al.  Arterial gene transfer of the TGF-beta signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF. , 2009, Cardiovascular research.

[51]  R. Kalluri,et al.  Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. , 2009, The American journal of pathology.

[52]  J. Bertram,et al.  Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. , 2009, The American journal of pathology.

[53]  S. Rosenkranz,et al.  Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension , 2009, Clinical Research in Cardiology.

[54]  Y. Asano,et al.  Phosphorylation of Fli1 at Threonine 312 by Protein Kinase C δ Promotes Its Interaction with p300/CREB-Binding Protein-Associated Factor and Subsequent Acetylation in Response to Transforming Growth Factor β , 2009, Molecular and Cellular Biology.

[55]  D. Abraham,et al.  Overview of pathogenesis of systemic sclerosis. , 2006, Rheumatology.

[56]  A. Volpe,et al.  Cyclophosphamide treatment improves microvessel damage in systemic sclerosis , 2009, Clinical Rheumatology.

[57]  D. Furst,et al.  Correction: Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype? , 2008, PLoS ONE.

[58]  A. Laucevičius,et al.  The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function , 2008, Clinical Rheumatology.

[59]  K. Evangelou,et al.  Imatinib for the treatment of refractory, diffuse systemic sclerosis. , 2008, Rheumatology.

[60]  H. Ihn.  Autocrine TGF- signaling in the pathogenesis of systemic sclerosis , 2008 .

[61]  Stephen M. Schwartz,et al.  Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype? , 2008, PloS one.

[62]  H. Ihn.  Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. , 2008, Journal of dermatological science.

[63]  Y. Asano,et al.  Transforming Growth Factor-β Regulates DNA Binding Activity of Transcription Factor Fli1 by p300/CREB-binding Protein-associated Factor-dependent Acetylation* , 2007, Journal of Biological Chemistry.

[64]  M. Ballmaier,et al.  The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration. , 2007, Blood.

[65]  Xueli Yuan,et al.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis , 2007, Nature Medicine.

[66]  M. Cerinic,et al.  Flow‐Mediated Vasodilation and Carotid Intima‐Media Thickness in Systemic Sclerosis , 2007, Annals of the New York Academy of Sciences.

[67]  M. Yoder,et al.  Working hypothesis to redefine endothelial progenitor cells , 2007, Leukemia.

[68]  Y. Shoenfeld,et al.  Endothelial dysfunction precedes atherosclerosis in systemic sclerosis--relevance for prevention of vascular complications. , 2007, Rheumatology.

[69]  G. Mancia,et al.  Effects of prostaglandin E1α cyclodestrin treatment on endothelial dysfunction in patients with systemic sclerosis , 2007 .

[70]  B. Thiers.  Cyclophosphamide versus Placebo in Scleroderma Lung Disease , 2007 .

[71]  G. Mancia,et al.  Effects of prostaglandin E1alpha cyclodextrin [corrected] treatment on endothelial dysfunction in patients with systemic sclerosis. , 2007, Journal of hypertension.

[72]  P. Emery,et al.  A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.

[73]  I. Chikanza,et al.  Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis , 2006, Nature Clinical Practice Rheumatology.

[74]  S. Gay,et al.  Angiogenesis and vasculogenesis in systemic sclerosis. , 2006, Rheumatology.

[75]  I. McKillop,et al.  Bosentan® inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis , 2006, Clinical & Experimental Metastasis.

[76]  B. Kahaleh,et al.  Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. , 2006, Arthritis and rheumatism.

[77]  Xiaodong Zhou,et al.  Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. , 2006, Rheumatology.

[78]  C. Black,et al.  Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. , 2006, Rheumatology.

[79]  T. Matsushita,et al.  Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. , 2006, The Journal of rheumatology.

[80]  L. Chung,et al.  Digital ulcers in patients with systemic sclerosis. , 2006, Autoimmunity reviews.

[81]  P. Carmeliet,et al.  Principles and therapeutic implications of angiogenesis, vasculogenesis and arteriogenesis. , 2006, Handbook of experimental pharmacology.

[82]  D. Kass,et al.  Reduced Wall Compliance Suppresses Akt-Dependent Apoptosis Protection Stimulated by Pulse Perfusion , 2005, Circulation research.

[83]  L. Settas,et al.  Early T cell activation in the skin from patients with systemic sclerosis , 2005, Annals of the rheumatic diseases.

[84]  H. Ihn.  Scleroderma, fibroblasts, signaling, and excessive extracellular matrix , 2005, Current rheumatology reports.

[85]  Stefanie Dimmeler,et al.  Unchain my heart: the scientific foundations of cardiac repair. , 2005, The Journal of clinical investigation.

[86]  A. Kuryliszyn-Moskal,et al.  Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement , 2005, Clinical Rheumatology.

[87]  M. Mayes,et al.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. , 2004, Arthritis and rheumatism.

[88]  F. Luppi,et al.  Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis. , 2004, Arthritis and rheumatism.

[89]  Y. Ikeda,et al.  Defective vasculogenesis in systemic sclerosis , 2004, The Lancet.

[90]  M. Kahaleh,et al.  Raynaud phenomenon and the vascular disease in scleroderma , 1994, Current opinion in rheumatology.

[91]  C. Chizzolini.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples , 2004, Springer Seminars in Immunopathology.

[92]  J. Dayer,et al.  Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. , 2003, Arthritis and rheumatism.

[93]  D. Watson,et al.  Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. , 2003, The American journal of pathology.

[94]  I. Haznedaroglu,et al.  Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. , 2003, Arthritis and rheumatism.

[95]  M. Cerinic,et al.  Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. , 2003, Seminars in arthritis and rheumatism.

[96]  Saptarsi M. Haldar,et al.  Wall Stiffness Suppresses Akt/eNOS and Cytoprotection in Pulse-Perfused Endothelium , 2003, Hypertension.

[97]  M. Conforti,et al.  Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers , 2002, Arthritis research.

[98]  S. Rantapää-Dahlqvist,et al.  Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. , 2002, Arthritis and rheumatism.

[99]  M. Hasegawa,et al.  Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. , 2001, Journal of dermatological science.

[100]  M. A. Hamid,et al.  Circulating soluble adhesion molecules in patients with systemic sclerosis: correlation between circulating soluble vascular cell adhesion molecule-1 (sVCAM-1) and impaired left ventricular diastolic function , 2000, Rheumatology International.

[101]  N. Sepp,et al.  Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. , 2000, Arthritis and rheumatism.

[102]  M. Jayson,et al.  Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin , 1999, The Journal of pathology.

[103]  M. Kahaleh,et al.  γδ Receptor Bearing T Cells in Scleroderma: Enhanced Interaction with Vascular Endothelial Cellsin Vitro , 1999 .

[104]  M. Kahaleh,et al.  Gammadelta receptor bearing T cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro. , 1999, Clinical immunology.

[105]  J. Lekakis,et al.  Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. , 1998, The American journal of cardiology.

[106]  R. Rezzonico,et al.  Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. , 1998, Arthritis and rheumatism.

[107]  J. Lekakis,et al.  Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. , 1998, American heart journal.

[108]  M. Fujimoto,et al.  Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. , 1998, British journal of rheumatology.

[109]  M. Matucci-Cerinic,et al.  Circulating Vδ1 + T cells are activated and accumulate in the skin of systemic sclerosis patients , 1998 .

[110]  M. Matucci-Cerinic,et al.  Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. , 1998, Arthritis and rheumatism.

[111]  G. Pizzolo,et al.  Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. , 1997, The American journal of pathology.

[112]  M. Fujimoto,et al.  Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. , 1997, British journal of rheumatology.

[113]  J. Piette,et al.  Antiendothelial cell antibodies: useful markers of systemic sclerosis. , 1997, The American journal of medicine.

[114]  M. Greaves,et al.  Antibodies to membranes of endothelial cells and fibroblasts in scleroderma , 1996, Clinical and experimental immunology.

[115]  M. Gershwin,et al.  Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. , 1996, The Journal of clinical investigation.

[116]  C. Ferri,et al.  Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? , 1996, The Journal of rheumatology.

[117]  W E Haefeli,et al.  Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. , 1995, Circulation.

[118]  M. Kahaleh.  Raynaud's phenomenon and vascular disease in scleroderma. , 1994, Current opinion in rheumatology.

[119]  P. Sfikakis,et al.  Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. , 1993, Clinical immunology and immunopathology.

[120]  J. K. Lloyd,et al.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis , 1992, The Lancet.

[121]  A. Freemont,et al.  Sequential dermal microvascular and perivascular changes in the development of scleroderma , 1992, The Journal of pathology.

[122]  N. Suzuki,et al.  Significance of plasma endothelin-1 levels in patients with systemic sclerosis. , 1992, The Journal of rheumatology.

[123]  P. Woo,et al.  Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. , 1988, Clinical and experimental immunology.